This is an aggregated industry headline. Read the full story at FiercePharma →
Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories.
By FiercePharma
· Jul 20, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last …
The WeekBriefing
CMS and state actions under the American Rescue Plan Act and later legislation have made yearlong postpartum c…
The WeekSTAT News ↗
"Pandemics should be viewed and combated as threats to national security," write David Blumenthal and James A.…